NEW YORK (GenomeWeb News) – Circulating tumor cell diagnostics developer Epic Sciences has appointed Murali Prahalad to be president and CEO.

Prahalad formerly held multiple posts at Life Technologies, and most recently he was VP of corporate strategies. In that role, he helped shape investment priorities across Life Tech’s research tools, clinical diagnostics, and applied markets portfolios, said Epic in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.